

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): May 2, 2022

**Silverback Therapeutics, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-39756**  
(Commission  
File Number)

**81-1489190**  
(IRS Employer  
Identification No.)

**500 Fairview Ave N, Suite 600**  
**Seattle, Washington**  
(Address of principal executive offices)

**98109**  
(Zip Code)

Registrant's telephone number, including area code: (206) 456-2900

N/A  
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.0001 par value per share	SBTX	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

**Item 1.02 Termination of a Material Definitive Agreement.**

On May 2, 2022, Silverback Therapeutics, Inc. (the “Company”) delivered a notice of termination with respect to the sublease agreement (the “Sublease”) with Delta Dental of Washington (“Sublandlord”), dated July 1, 2021, for the sublease of approximately 9,188 square feet of rentable area of the building located at 400 Fairview Avenue North, Seattle, Washington 98109. The termination is effective as of July 31, 2022. A description of the material terms of the Sublease was included in Item 1.01 of the Current Report on Form 8-K filed by the Company on July 2, 2021, which is incorporated herein by reference. In connection with the termination, the Company is obligated to pay to Sublandlord a termination fee in the amount of \$28,330.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**SILVERBACK THERAPEUTICS, INC.**

By: /s/ Laura Shawver, Ph.D.

\_\_\_\_\_  
Laura Shawver, Ph.D.

Chief Executive Officer

Dated: May 6, 2022